32 proton therapy centers installed by IBA are treating patients confirming IBA experience leadership
Louvain-la-Neuve, Belgium, 8 November, 2019 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that the first patients have begun their treatment at the proton therapy center in Dimitrovgrad, Russia, which is a part of the Federal High-Tech Center of Medical Radiology of the Federal Medico-Biological Agency of Russia (FMBA).
On September 27th, the proton therapy center in Dimitrovgrad began the treatment of four patients. The IBA Proteus®PLUS* multiple room solution installed in Dimitrovgrad is now in operation and available to treat patients. The center is equipped with the most advanced technology available today in Intensity Modulated Proton Therapy (IMPT).
This additional center brings the total number of proton therapy centers in operation installed by IBA to 32 (23 Proteus®PLUS and 9 Proteus®ONE*). This new milestone strengthens IBA’s position as the undisputed leader in proton therapy equipment and services as IBA operates almost half (45%) of all proton therapy centers worldwide. At the end of 2018, 56%[1] of patients who have received proton therapy have been treated on an IBA system, illustrating IBA’s unrivalled experience equipping clinicians with the most advanced technology for their patients who need proton therapy.
Kirill Makarenko, Vice-President and Director of the IBA’s Representative office in Russia, commented: “The first treatments in Dimitrovgrad are the first of its kind available to cancer patients from the Ulyanovsky region and will be offered to patients from the whole Russian Federation. This important milestone opens the path towards new key areas of research and treatment.”
-END-
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
* Proteus®PLUS and Proteus®ONE is the brand name of Proteus®235
For further information, please contact:
IBA
Aymeric Harmant
Global Marketing Proton Therapy Director
+32 475 940 975
aymeric.harmant@iba-group.com
[1] Data from PTCOG 2019 – commercial centers only